The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2023 | Detecting ctDNA in patients with NSCLC receiving adagrasib
Pasi Jänne, MD, PhD, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, describes the role of ctDNA analysis in monitoring treatment outcomes in patients with advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC). The ctDNA levels of patients receiving adagrasib were tracked, and patients who had lower levels post-treatment had better outcomes. For patients whose ctDNA levels remain high, treatment escalation is an option. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
